News

<p>The company said that as a result of the encouraging results seen in trials of the drug to date, it intends to meet with regulatory agencies in the

<p>The companies hope that the partnership will result in novel therapeutic approaches for treating cancers by speeding up the discovery of innovative compounds with potential use in therapeutic

US-based Voyager terminated the trial of Memryte, an investigational drug for the treatment of Alzheimer’s disease, in October 2006. The pharmaceutical company’s pipeline Alzheimer’s disease treatment uses Durect’s

The National Audit Office (NAO) study, which included a survey of 1,000 general practitioners and prescribing advisers in Primary Care Trusts (PCTs), concluded that generic drugs offer scope

The tentative approval concerns the marketing and manufacturing of the fexofenadine hydrochloride tablets in 30mg, 60mg and 180mg doses. The drug is indicated for the relief of symptoms

The new study is an open-label, dose escalation study designed to assess the safety and pharmacokinetics of bavituximab in approximately 24 patients chronically infected with HCV and HIV.

Researchers for the cancer charity analyzed 16 trials involving LHRH agonists and found them to be as effective as conventional chemotherapy for many pre-menopausal breast cancer patients with

The study is enrolling healthy overweight and obese volunteers to evaluate the safety, tolerability, and pharmacokinetics of ascending single doses of intravenously administered trodusquemine (MSI- 1436). This ascending

GelSite polymer is a novel high molecular weight ionic polysaccharide developed by DelSite. With the National Institutes of Health’s (NIH) novel polysaccharide technology, GelSite polymer may be chemically